Malawi Integrated HIV Program Report 2019 Q2

  • Scale-up of integrated HIV services had reached the following number of sites:
    • 759 static and 139 outreach HIV testing sites
    • 749 (static) ART sites; 616 of these started at least one pregnant or breastfeeding woman and 720 started asymptomatic patients (Test & Treat) this quarter
    • 691 sites with HIV-exposed children in follow-up
  • 1,007,296 persons were tested for HIV and received their results; 207,831 (21%) accessed HIV testing for the first time; 799,465 (79%) were repeat testers and 33,613 (3%) of these received confirmatory testing (after having tested positive in the past). 28,912 (2.8%) clients received a positive result for the first time1.
  • 19,675 (98%) of 20,078 blood units collected were screened for (at least) HIV, hepatitis B and syphilis
  • 160,860 (97%) of 165,689 women at ANC had their HIV status ascertained; 10,830 (7%) of these were HIV positive. 134,297 (94%) of 142,538 at maternity had their HIV status ascertained 9,845 (7%) of these were HIV positive.
  • 28,318 patients started ART this quarter; 67% were classified as asymptomatic / in WHO stage 1 and started under the “Test & Treat” policy.
  • 819,947 patients were alive and on ART by end of June 2019. This means that 78% of the estimated 1,066,811 HIV positive population was on ART. ART coverage was 68% (46,754/ 68,727) for children and 78% (781,570 / 998,084) for adults.
  • 104,156 (92%) of viral load results from routine monitoring were 99%) of an estimated 10,932 2 HIV infected pregnant women in Malawi were on ART this quarter. __8,461 (72%) of these were already on ART when getting pregnant and 3,303 (28%) started ART during pregnancy/delivery.
  • An additional 1,160 breastfeeding women started ART in WHO stage 1 or 2.
  • 78%, and 70% of women started while pregnant or breastfeeding were retained on ART at 6 and 12 months after initiation, respectively.
  • 9,037 (7%) of infants discharged alive from maternity were known to be HIV exposed, 8,456 (94%) of these received ARV prophylaxis (nevirapine).

Data and Resources

Additional Info

Field Value
Program Area Care and Treatment
Year 2019
Author
Author Email cmkandawire@hivmw.org
Visibility